Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation
暂无分享,去创建一个
S. Larson | M. Gonen | R. Tuttle | K. Pentlow | R. Qualey | R. Grewal | Christina E Pentlow | Lauren Natbony | Michael Tuttle
[1] C. Harmer,et al. Salivary gland toxicity after radioiodine therapy for thyroid cancer. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).
[2] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[3] R. Solans,et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] D. van Nostrand,et al. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] R. Tuttle,et al. Medical management of thyroid cancer: a risk adapted approach , 2008, Journal of surgical oncology.
[6] S. Mandel,et al. Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.
[7] R. Tuttle,et al. Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.
[8] M. Tuncel,et al. Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine Treatment , 2002, Clinical nuclear medicine.
[9] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] C. Edmonds,et al. The long-term hazards of the treatment of thyroid cancer with radioiodine. , 1986, The British journal of radiology.
[11] Markus Luster,et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] S. J. Wang,et al. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. , 1996, Clinical nuclear medicine.
[13] G. Braunstein,et al. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] R. Kloos,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .
[15] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[16] F. Grünwald,et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] S. Larson,et al. Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.
[18] J. Dudeck,et al. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany , 2000, European Journal of Nuclear Medicine.
[19] B. Malpani,et al. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. , 1996, International journal of radiation oncology, biology, physics.
[20] M. Schlumberger. [Papillary and follicular thyroid carcinoma]. , 2000, Annales d'endocrinologie.
[21] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[22] R. Kloos,et al. Sodium iodide symporter in health and disease. , 2001, Thyroid : official journal of the American Thyroid Association.
[23] P. Zanzonico,et al. Radiation dose to patients and relatives incident to 131I therapy. , 1997, Thyroid : official journal of the American Thyroid Association.
[24] C. Kirsch,et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] S. Purisch,et al. Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.